Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.

  title={Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.},
  author={Erling Tronvik and Lars Jacob Stovner and Grethe Helde and Trond Sand and Gunnar Bovim},
  volume={289 1},
CONTEXT There is a paucity of effective, well-tolerated drugs available for migraine prophylaxis. OBJECTIVE To determine whether treatment with the angiotensin II receptor blocker candesartan is effective as a migraine-prophylactic drug. DESIGN AND SETTING Randomized, double-blind, placebo-controlled crossover study performed in a Norwegian neurological outpatient clinic from January 2001 to February 2002. PATIENTS Sixty patients aged 18 to 65 years with 2 to 6 migraine attacks per month… 

Tables from this paper

Lisinopril as a prophylactic agent for migraine: a randomised double blind placebo controlled cross over prospective study in Kashmir

This study favours lisinopril as an effective prophylactic drug for migraine, though of significant frequency, have been mild to moderate in severity but were well tolerated by even normotensive subjects.

Randomised trial on episodic cluster headache with an angiotensin II receptor blocker

Post-hoc statistics suitable to describe the temporal changes in cluster headache indicate that conduction of future larger studies may be justified, and the difference between the candesartan and placebo group was not significant with the pre-planned non-parametric ranking test.

Topiramate for migraine prevention: a randomized controlled trial.

Topiramate showed significant efficacy in migraine prevention within the first month of treatment, an effect maintained for the duration of the double-blind phase.

Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial

The results support the previous suggestions on usage of ACE inhibitors in migraine prophylaxis and Enalapril according to its effect in decreasing the frequency, severity, and duration of headaches.

Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study

C candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics.

The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials

Summary data from four crossover trials evaluating preventive treatment in adult migraine showed that few dropped out after the first period, and no period or carryover effect was found.

Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

Lasmiditan was more effective than placebo for the acute treatment of migraine in patients concurrently using migraine preventive medications and rates of adverse events were similar for patients using and not using preventive medications.

Angiotensin II receptor blockers: a new possible treatment for chronic migraine?

It is considered desirable large controlled, randomized trials to assess the effectiveness of ARBs both in CM hypertensive patients and in patients who do not require anti-hypertensive therapy; furthermore there are desirable comparative studies between the various ARB inhibitors to assay any intermolecular differences in efficacy.

Candesartan in migraine prevention: results from a retrospective real-world study

Canesartan yields clinical benefits in difficult-to-treat migraine patients, irrespective of previous failed preventives, and is associated with reduced odds of headache benefit.



Antiepileptic Drugs in Migraine Prevention

Large, double‐blind, placebo‐controlled trials may prove the effectiveness of novel antiepileptic drugs in migraine prevention.

Sodium Valproate in The Prophylactic Treatment of Migraine: A Double-Blind Study Versus Placebo

The efficacy of sodium valproate (Depalept) versus placebo in the treatment of migraine was evaluated in a double-blind randomized cross-over study and the drug was well tolerated and proved to be an effective treatment in migraine.

The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers.

Uncertainties regarding the relative merits of various treatment modalities are largely caused by lack of adherence to specific requirements for clinical trials on migraine prophylaxis.

Efficacy and Tolerability in Migraine Prophylaxis of Flunarizine in Reduced Doses: A Comparison with Propranolol 160 Mg Daily

The results of this equivalence trial show that 10 mg flunarizine daily with a drug-free weekend is at least as effective as 160 mg propranolol in the prophylaxis of migraine for all evaluated parameters (one-sided equivalence tests) after 16 weeks of treatment.

A Quantification of the Placebo Response in Migraine Prophylaxis

It is proposed that if the percentage of responders in an open-label prophylactic trial in migraine is above 35-40%, or if a reduction in migraine attack frequency is found of 40% or more, further studies are indicated to determine the prophyllactic activity of the drug.

Effects of Candesartan on Cough and Bronchial Hyperresponsiveness in Mildly to Moderately Hypertensive Patients With Symptomatic Asthma

It is suggested that candesartan is as effective and safe as calcium antagonists in the treatment of hypertension associated with symptomatic asthma.

Candesartan cilexetil: an angiotensin II-receptor blocker.

  • S. SeeA. L. Stirling
  • Medicine
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2000
It appears that candesartan can decrease renal perfusion without adversely affecting renal blood flow and may mediate a decrease in albuminuria in hypertensive patients with type 2 diabetes.

Angiotensin-II receptor antagonists: their place in therapy.

  • J. Kirk
  • Biology, Medicine
    American family physician
  • 1999
Clinical trials indicate that angiotensin-II receptor antagonists are effective and safe in the treatment of hypertension, and their use in congestive heart failure and renal disease is under investigation.

Prevention of migraine.

It is regrettable that you should take such a discouraging attitude in this important public health field, and it is not too early to start a public educational campaign based on the considerable knowledge of risk factors which has already accrued.